Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 172


Topotecan-carboplatin-etoposide combination as 1st line treatment in patients with small cell lung cancer.

Zarogoulidis K, Mylonaki E, Kakavelas P, Zarogoulidis P, Tsiouda T, Rapti E, Lithoxopoulou H, Zarogoulidou V, Kontakiotis T; Hellenic Pulmonary Oncology Study Group (HE.P.O.G.).

Lung Cancer. 2009 Nov;66(2):226-30. doi: 10.1016/j.lungcan.2009.02.003. Epub 2009 Mar 24.


A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer.

Garst J, Herndon JE 2nd, Shafman T, Campagna L, Blackwell S, Padilla K, Bjurstrom T, Andrews C, Maravich-May D, Anderson E, Crawford J.

Clin Drug Investig. 2006;26(5):257-66.


Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.

Miller AA, Al Omari A, Murry DJ, Case D.

Lung Cancer. 2006 Dec;54(3):379-85. Epub 2006 Oct 16.


A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.

Gillenwater HH, McCune JS, Lindley C, Faucette S, Shord S, Donahue A, Socinski MA, Stewart CF, Zamboni WC, Kirstein MN, Moore D.

Cancer Invest. 2005;23(6):511-9.


A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.

Mok TS, Wong H, Zee B, Yu KH, Leung TW, Lee TW, Yim A, Chan AT, Yeo W, Chak K, Johnson P.

Cancer. 2002 Oct 1;95(7):1511-9.


Phase I and pharmacologic study of sequential topotecan, carboplatin, and etoposide.

Miller AA, Niell HB.

Lung Cancer. 2001 Aug-Sep;33(2-3):241-8.


Cisplatin-etoposide alternating with topotecan in patients with extensive stage small cell lung cancer (SCLC). A multicenter phase II study.

Mavroudis D, Veslemes M, Kouroussis Ch, Tzanakis N, Ferdoutsis E, Toumbis M, Ziotopoulos P, Agelidou M, Tselepatiotis E, Kalbakis K, Souglakos J, Magkanas E, Samonis G, Georgoulias V; Hellenic Oncology Research Group.

Lung Cancer. 2002 Oct;38(1):59-63.


Topotecan and etoposide as first-line therapy for extensive disease small cell lung cancer: a phase II trial of a platinum-free regimen.

Reck M, Groth G, Buchholz E, Goetz E, Gatzemeier U, Manegold C.

Lung Cancer. 2005 Jun;48(3):409-13. Epub 2005 Jan 23.


Sequential administration of cisplatin-etoposide followed by topotecan in patients with extensive stage small cell lung cancer. A multicenter phase II study.

Mavroudis D, Pavlakou G, Blazoyiannakis G, Veslemes M, Apostolopoulou F, Kouroussis Ch, Kakolyris S, Agelaki S, Androulakis N, Vardakis N, Magkanas E, Samonis G, Georgoulias V.

Lung Cancer. 2003 Jan;39(1):71-6.


A randomised phase II study of the efficacy and safety of intravenous topotecan in combination with either cisplatin or etoposide in patients with untreated extensive disease small-cell lung cancer.

Quoix E, Breton JL, Gervais R, Wilson J, Schramel F, Cardenal F, Ross G, Preston A, Lymboura M, Mattson K.

Lung Cancer. 2005 Aug;49(2):253-61.


Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.

Hainsworth JD, Morrissey LH, Scullin DC Jr, Houston GA, Prasthofer EF, Gray JR, Burris HA 3rd, Greco FA.

Cancer. 2002 May 1;94(9):2426-33.


Triplet combination of carboplatin, irinotecan, and etoposide in the first-line treatment of extensive small-cell lung cancer: a single-institution phase II study.

Charpidou A, Tsagouli S, Tsimpoukis S, Vassias A, Makrilia N, Stratakos G, Gkiozos I, Syrigos K.

Anticancer Drugs. 2010 Jul;21(6):651-5. doi: 10.1097/CAD.0b013e3283393718.


Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial.

Greco FA, Thompson DS, Morrissey LH, Erland JB, Burris HA 3rd, Spigel DR, Joseph G, Corso SW, Spremulli E, Hainsworth JD.

Oncologist. 2005 Oct;10(9):728-33.


Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.

Socinski MA, Smit EF, Lorigan P, Konduri K, Reck M, Szczesna A, Blakely J, Serwatowski P, Karaseva NA, Ciuleanu T, Jassem J, Dediu M, Hong S, Visseren-Grul C, Hanauske AR, Obasaju CK, Guba SC, Thatcher N.

J Clin Oncol. 2009 Oct 1;27(28):4787-92. doi: 10.1200/JCO.2009.23.1548. Epub 2009 Aug 31.


Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914.

Hesketh PJ, McCoy J, Dunphy FR 2nd, Bearden JD 3rd, Weiss GR, Giguere JK, Atkins JN, Dakhil SR, Kelly K, Crowley JJ, Gandara DR.

J Thorac Oncol. 2006 Nov;1(9):991-5.


Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer.

Fetscher S, Brugger W, Engelhardt R, Kanz L, Hasse J, Frommhold H, Wenger M, Lange W, Mertelsmann R.

Ann Oncol. 1997 Jan;8(1):49-56.


Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities.

Hainsworth JD, Gray JR, Stroup SL, Kalman LA, Patten JE, Hopkins LG, Thomas M, Greco FA.

J Clin Oncol. 1997 Dec;15(12):3464-70.


Sequential dose-dense paclitaxel followed by topotecan in untreated extensive-stage small-cell lung cancer: a Spanish Lung Cancer Group phase II study.

Felip E, Rosell R, Domine M, Santomé L, Garrido P, Font A, Carrato A, Terrasa J, Vadell C, Mañe JM, Baselga J; Spanish Lung Cancer Group.

Ann Oncol. 2003 Oct;14(10):1549-54.


Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002.

Miller AA, Wang XF, Bogart JA, Hodgson LD, Rocha Lima CM, Radford JE, Vokes EE, Green MR; Cancer and Leukemia Group B (CALGB).

J Thorac Oncol. 2007 Jul;2(7):645-51.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk